
Erasca Faces Class Action Lawsuit Over Alleged Oncology Drug Misconduct
Investors who suffered significant losses in Erasca, Inc. have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit. The litigation alleges the biotech firm misled shareholders regarding the safety, competitive standing, and intellectual property security of its lead cancer treatment candidate, ERAS-0015.
























